Lykera biomed project
Lykera is a privately held biotech company based in Barcelona, Spain. The Company is developing biologics for the treatment of cancer by targeting not only the tumour cells but also the stromal cells and tumour angiogenesis.
Lykera’s most advanced product, LK-1 is a first in class antibody against the three tumour compartments. LK-1 has already the in vivo preclinical proof-of-principle and it is ready to enter regulatory preclinical phases.
Lykera’s vision stands for bringing innovative therapies for cancer treatment based on a global view of cancer. Innovation for future health.